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ABSTRACT 1 
Hypertension results from the interaction of genetic and acquired factors. IgG occurs 2 
in the form of different subclasses, of which the effector functions show significant 3 
variation. The detailed differences between the glycosylation profiles of the individual 4 
IgG subclasses may be lost in a profiling method for total IgG N-glycosylation. In this 5 
study, subclass-specific IgG Fc glycosylation profile was investigated in the four 6 
northwestern Chinese minority populations, namely, Uygur (UIG), Kazak (KZK), 7 
Kirgiz (KGZ) and Tajik (TJK), composed of 274 hypertensive patients and 356 8 
healthy controls. The results showed that 10 directly measured IgG N-glycan traits (i.e. 9 
IgG1G0F, IgG2G0F, IgG2G1FN, IgG2G1FS, IgG2G2S, IgG4G0F, IgG4G1FS, 10 
IgG4G1S, IgG4G2FS, and IgG4G2N) representing galactosylation and sialylation are 11 
significantly associated with hypertension, with IgG4 consistently showed weaker 12 
associations of its sialylation, across the four ethnic groups. We observed a modest 13 
improvement on the AUC of ROC-curve when the IgG Fc N-glycan traits are added 14 
into the glycan-based model (difference between AUCs, 0.044, 95% CI: 0.016-0.072, 15 
P= 0.002). The AUC of the diagnostic model indicated that the subclass-specific IgG 16 
Fc N-glycan profiles provide more information reinforcing current models utilizing 17 
age, gender, BMI and ethnicity, and demonstrate the potential of subclass-specific 18 
IgG Fc N-glycosylation profiles to serve as a biomarker for hypertension. Further 19 
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research is however required to determine the additive value of subclass-specific IgG 1 
Fc N-glycosylation on top of biomarkers which are currently used.  2 
  3 
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Summary Table 1 
What is known about topic? 2 
 The prevalence of hypertension in the Chinese minority populations residing in 3 
the northwestern China ranked at the forefront of China. 4 
 Previous studies showed an association between hypertension and IgG N-5 
glycome composition in European (i.e. Croatian Korčula, Croatian Vis, and 6 
Scottish Orkney), Asian (i.e. Chinese Han and Chinese Kazak) populations. 7 
 The relationship between IgG glycosylation and hypertension in other 8 
populations remains unknown. 9 
 Previous studies on total IgG N-glycans do not allow to distinguish between Fc 10 
and Fab associated N-glycans, as such the contribution of changes in Fab N-11 
glycosylation cannot be excluded. 12 
What this study adds? 13 
 This study provides evidence that the decreased IgG galactosylation and 14 
sialylation were correlated with hypertension in the four ethnic groups (i.e. Uygur, 15 
Kazak, Kirgiz and Tajik) residing in the northwestern China. 16 
 We describe the differences between the plasma Fc glycosylation profiles 17 
particularly of IgG1, IgG2 and IgG4 in detail, which may be lost in a profiling 18 
method for total IgG N-glycosylation. 19 
 The AUC of the glycan-based model indicated that the IgG glycan profiles 20 
provide more information reinforcing current models utilizing gender, age, BMI 21 
and ethnicity, and demonstrate the potential of subclass-specific IgG Fc N-22 
glycosylation profiles to serve as a biomarker for hypertension. 23 
  24 
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INTRODUCTION  1 
Hypertension is a chronic, asymptomatic condition that increases individuals’ risk 2 
of developing several diseases, including coronary artery disease, stroke, and renal 3 
failure.1 Hypertension was the leading risk factor for global disease in 2010,2 and over 4 
20% of adults (⩾18 years) worldwide were hypertensive, accounting for nearly 10 5 
million deaths in 2014.3 The prevalence of hypertension continues to increase in 6 
China from 18% in 2002 to 23.2% in 2015,4 in which participants were recruited by 7 
the use of a stratified multistage cluster sampling design. 8 
Glycosylation is one of the most widespread post-translational modifications 9 
capable of increasing significant structural diversity to proteins, which is known to 10 
reflect the physiological state of an organism and changes thereof.5 For 11 
immunoglobulin G (IgG), which occupies a central role in the immune system, it is 12 
known that the conserved N-glycan located at asparagine 297 on the fragment 13 
crystallisable (Fc) part of IgG can modulate inflammatory responses: a lack of core 14 
fucose, galactose and N-acetylneuraminic (sialic) acid increases the ability of IgG to 15 
induce antibody-dependent cell-mediated cytotoxicity (ADCC).6 In spite of the 16 
pivotal role of IgG glycosylation in many physiological and pathological processes, 17 
the monitoring of IgG glycosylation is often neglected in clinical and immunological 18 
research.7  19 
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IgGs consist of four subclasses (i.e. IgG1–4), which bind their antigen targets via 1 
the fragment antigen binding (Fab) domain and exert their effector functions via the 2 
fragment crystallizable (Fc) domain.8 Fc glycans are essential structural components 3 
of the IgG molecule and minor changes in glycan composition can significantly alter 4 
the conformation of the Fc region changing the interaction with receptor proteins and 5 
thus modulating the effector functions of IgG. The assignment of glycans to the 6 
specific Fc glycosylation sites of IgG subclasses is pivotal for deducing the functional 7 
implications of the observed glycosylation features.9 Additionally, each of the IgG 8 
subclasses has a unique binding profile to each Fc gamma receptors (FcγRs), and their 9 
expression profiles are highly variable between different immune cells of myeloid and 10 
NK cell origin.10 Most of the modulating effects of IgG Fc glycans have been reported 11 
for IgG1 and may not apply to IgG2, stressing the relevance of subclass and site 12 
specific IgG glycosylation profiling.9 The differences between the Fc N-glycosylation 13 
profiles of the individual IgG subclasses may be lost in total IgG N-glycosylation (Fc 14 
and Fab associated N-glycans). 15 
The prevalence of hypertension in the Chinese minority populations residing in 16 
the Xinjiang Uygur Autonomous Region located in the northwestern China is 17 
relatively higher than that in the Chinese Han in China.11 The northwestern Chinese 18 
minority populations, including Uygur (UIG), Kazak (KZK), Kirgiz (KGZ) and Tajik 19 
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(TJK), etc., are overwhelmingly Muslim, and have their own language, religious 1 
beliefs and lifestyles differed largely from either Han Chinese or European 2 
populations.12 They are classically well-defined isolated populations, and these ethnic 3 
groups differ substantially in terms of morphological and genetic characteristics.13 4 
These differences in genetics and environmental factors together with abnormal 5 
higher prevalence of hypertension might imply different pathogenesis of hypertension.  6 
Our previous study has reported that individual variation of N-glycosylation of 7 
IgG might contribute to hypertension in European (i.e. Croatian Korčula, Croatian 8 
Vis, and Scottish Orkney) and Asian (i.e. Chinese Han and Chinese Kazak) 9 
populations.14,15 Investigating other populations would be an expedient way to 10 
evaluate the generalizability of the current findings. In this study, we further validated 11 
these findings by investigating Fc N-glycosylation profiles of human IgG subclasses, 12 
investigated to what extent the Fc N-glycome of IgG subclasses correlates with the 13 
occurrence of hypertension, and demonstrated the potential of subclass-specific IgG 14 
Fc N-glycosylation profiles to serve as a biomarker for hypertension in the four 15 
northwestern Chinese minority populations.  16 
MATERIALS AND METHODS 17 
Study population 18 
This population-based, case-control survey was conducted in the Xinjiang Uygur 19 
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Autonomous Region, China, from August 2014 to August 2016. A total of 630 1 
participants were recruited from 170 UIG, 150 KZK, 168 KGZ and 142 TJK. The 2 
demographic characteristics of the participants, including ethnicity, gender, age, and 3 
history of medications, were collected by a questionnaire. 4 
Participants were included if they aged more than 18 years, self-reported the 5 
respective UIG, KZK, KGZ and TJK ethnicity without intermarriage history with 6 
other ethnic groups within at least the past three generations. Individuals with a 7 
diagnosis of specific severe diseases concerning the cardiovascular system, 8 
respiratory system, genitourinary system, digestive system, and hematic system, were 9 
excluded. All participants gave written informed consent. This study was approved by 10 
the local community leaders and the ethics committee of the Capital Medical 11 
University, Beijing, China.  12 
Anthropometric measurements, including weight, height, etc., were obtained 13 
using standardized techniques.14 The body mass index (BMI) was calculated by the 14 
formula weight (in kilograms)/height (in square meters). Peripheral bloods of the 15 
participants were collected in EDTA-anti-coagulated tubes after an overnight fast. 16 
Fasting blood glucose (FBG), high-density lipoprotein cholesterol (HDL), low-density 17 
lipoprotein cholesterol (LDL), triglycerides (TG) and serum total cholesterol (TC) 18 
were assayed under the standard procedures in the local hospital. 19 
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Dyslipidemia defined based on the 2016 Guidelines for Prevention and 1 
Treatment of Dyslipidemia in Adults in China: TC⩾6.2 mmol/L, TG⩾2.3 2 
mmol/L, LDL⩾4.1 mmol/L or HDL<1.0 mmol/L.16 Systolic blood pressure (SBP) 3 
and diastolic blood pressure (DBP) were measured three times in a day with a 4 
mercury sphygmomanometer. Hypertension was defined as an average SBP⩾140 5 
mmHg or an average DBP⩾90 mmHg, or self-reported current hypertension.17 6 
IgG Fc N-glycopeptide analysis 7 
IgG was isolated from the plasma samples of all the participants after overnight 8 
fasting, and each IgG subclass was analyzed by nano-reverse phase UPLC-MS using 9 
a sheath-flow ESI sprayer interface as described previously.18,19 Glycopeptide data 10 
were extracted by in-house python script. In short, m/z was recalibrated internally, 11 
and intensities of top four isotopologues per charge per glycopeptide were extracted 12 
from LC elution bins. Glycopeptide area was produced by summing intensities across 13 
all relevant isotopologues and charge states. The N-glycopeptide signals were 14 
normalized by dividing each by the total signal intensity of all N-glycopeptides 15 
belonging to that subclass, yielding percentage data amounting to 100% per subclass. 16 
Along with the 20 glycopeptide structures per subclass of IgG, an additional 7 derived 17 
traits (agalactosylation, galactosylation, monogalactosylation, digalactosylation, 18 
sialylation, bisecting N-acetylglucosamine [GlcNAc] and fucosylation) representing 19 
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composite traits were  defined by taking into account these glycopeptide structures 1 
amounts per each subclass:8,14 2 
Agalactosylation (A) = G0 + G0F + G0FN + G0N 3 
Galactosylation (G) = G1 + G1F + G1FN + G1N + G2 + G2F + G2FN + G2N 4 
Monogalactosylation (M) = G1 + G1F + G1FN + G1N 5 
Digalactosylation (D) = G2 + G2F + G2FN + G2N 6 
Sialylation (S) = G1FS + G1FNS + G1S + G1NS + G2FS + G2FNS + G2NS + 7 
G2S 8 
Bisecting GlcNAc (B) = G0FN + G0N + G1FN + G1FNS + G1N + G1NS + 9 
G2FN + G2FNS + G2NS + G2N 10 
Fucosylation (F) = G0F + G0FN + G1F + G1FN + G1FNS + G1FS + G2F + 11 
G2FN + G2FNS + G2FS 12 
Statistical analysis 13 
To remove experimental variation from measurements, normalization and batch 14 
correction were performed on the LC-MS glycopeptide data.8 Normality distributions 15 
were checked by the Kolmogorov-Smirnov tests. Continuous variables underlying 16 
normality distribution were described by mean together with standard deviation (SD), 17 
otherwise median together with interquartile range were used. Considering that nearly 18 
all the glycan traits cannot be assumed normal distributed, Mann-Whitney U test was 19 
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used to compare the differences of IgG subclass-specific Fc glycopeptides between 1 
the hypertension patients and the healthy controls. Associations between glycans and 2 
disease status were performed using a logistic regression with age, gender, ethnicity, 3 
BMI, FBG and dyslipidemia included as covariates. Pooling analysis was carried out 4 
by introducing dummy variables representing the different ethnic groups.  5 
Dimension reduction based on LASSO (least absolute shrinkage and selection 6 
operator) method was performed to select N-glycopeptide traits used in the 7 
discriminant analysis.14 To classify the hypertension patients with the healthy controls, 8 
a logistic regression model was applied. Two different predicted models were 9 
considered: a baseline model included gender, age, BMI and ethnicity as the 10 
covariates, and a glycan-based model included the significantly differed IgG Fc 11 
glycopeptides together with the aforementioned covariates. Receiver operating 12 
characteristic (ROC) curve analyses were used to evaluate the diagnostic ability in 13 
classifying the hypertension patients from the healthy controls. The area under the 14 
receiver operating characteristic curve (AUC) of the 2 classification models were 15 
compared using MedCalc (Version 17.9.7). 16 
All the analyses were performed using the SPSS (Version 21.0, IBM) software 17 
and R packages (Version 2.7.2). For the multiple corrections, the false discovery rate 18 
(FDR) was used based on the Benjamini-Hochberg procedure.20 All the tests were 2-19 
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sided, and P < 0.05 was considered statistically significant. 1 
RESULTS 2 
By performing LC-ESI-MS analysis on IgG glycopeptides, Fc glycosylation 3 
profiles of IgG1, IgG2 and IgG4 were determined for 630 participants (i.e. 170 UIG, 4 
150 KZK, 168 KGZ, and 142 TJK) in the study. Fc glycopeptides of IgG2 and IgG3 5 
share the same peptide sequence,21 and so the commonly used protein G enrichment 6 
of IgG gives a joint profile for both IgG2 and IgG3. It has been shown to capture IgG1, 7 
2 and 4, but has a much lower binding affinity for IgG3 under the enrichment 8 
conditions we use,7 thus allowing for near-separate glycoprofiling of IgG2. 9 
All 630 participants provided complete biometrics and glycan level data, and 10 
were therefore used in the further analyses. Descriptive information on the 11 
hypertension patients and the healthy controls for each of the four ethnic groups are 12 
shown separately (Table S1) and pooled together in Table 1. The age, gender, BMI, 13 
SBP, DBP, TC, HDL, LDL and FBG significantly differed in hypertension patients 14 
compared to healthy controls. 15 
The comparisons of directly measured subclass-specific IgG Fc glycomic 16 
composition between hypertension patients and healthy controls of each ethnicity and 17 
of the pooled participants from all four ethnic groups are shown in Table S2, while 18 
derived traits are shown in Table S3 and Figure 1. Subclass-specific IgG Fc N-19 
14 
 
glycopeptides were significantly associated with hypertension in the pooled 1 
participants from all four ethnic groups after controlling for gender, age, BMI, 2 
dyslipidemia, FBG and ethnicity as summarized in Table S2 and Table S3. Ten 3 
directly measured IgG subclass-specific Fc glycopeptide structures and 14 derived 4 
glycan traits are significantly associated with hypertension in the pooling of the four 5 
ethnic groups, primarily reflecting the decrease of galactosylation and sialylation in 6 
hypertension patients.  Subclass-specific IgG Fc glycopeptides that statistically 7 
differred between the hypertensive patients and healthy controls in the pooling of four 8 
ethnic groups were not consistently significant among the comparisons between each 9 
ethnicity, although these differences were in similar trends (Table S2 and Table S3). 10 
Two different models were built using Logistic regression (Table 4, Figure 2). 11 
The AUC of 0.688 (95% CI: 0.650-0.724) in the baseline model utilized gender, age, 12 
BMI and ethnicity as the covariates, and 0.732 (95% CI: 0.696-0.766) in the glycan-13 
based model utilized five significantly differed subclass-specific IgG Fc glycopeptide 14 
N-glycans (IgG1G0F, IgG2G0F, IgG4G0F, IgG4G2FS and IgG4G2N) together with 15 
the aforementioned covariates, respectively. The AUCs showed modest improvement 16 
in the glycan-based diagnostic model compared to the baseline model, with an 17 
increment of 0.044 (95% CI: 0.016-0.072, P = 0.002). 18 
DISCUSSION 19 
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Using LC-ESI-MS, this study represents the first comprehensive analysis of Fc 1 
N-glycosylation profiling of human IgG subclasses showing similar associations with 2 
hypertension in the four ethnic minorities in northwestern China. In this study, ten 3 
directly measured subclass-specific IgG Fc N-glycan traits indicative of 4 
galactosylation and sialylation presented a significant association with hypertension. 5 
The IgG subclasses displayed subtle differences in directly measured glycopeptide 6 
structures, with significant differences in sialylation resulting primarily between the 7 
IgG1 and IgG2 subclasses, the potential reason for any underlying difference in 8 
biological role. When the five selected glycan traits (IgG1G0F, IgG2G0F, IgG4G0F, 9 
IgG4G2FS and IgG4G2N) were added into the glycan-based model, the AUC showed 10 
modest improvement (difference between AUCs, 0.044, 95% CI: 0.016-0.072, P = 11 
0.002).  12 
We previously demonstrated that plasma N-glycome is associated with blood 13 
pressure, with increased triantennary glycans and decreased core-fucoseglycans in the 14 
subjects with elevated blood pressure, in both Chinese (Han and Kazak) and Croatian 15 
(Korčula and Vis).22 Previously we showed that galactosylation and sialylation of 16 
total IgG decreased, and fucosylated structures and bisecting GlcNAc of total IgG 17 
increased in patients of hypertension.15 In addition, 14 IgG subclass-specific Fc 18 
glycopeptide structures, along with one derived glycosylation trait in subclasses IgG2 19 
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and IgG4, are correlated with SBP and/or DBP in the Kazakh population.14 Here, we 1 
advanced the understanding of the association between the subclass-specific IgG Fc 2 
glycopeptides, which may be lost in total IgG N-glycosylation, and hypertension in 3 
the four northwestern Chinese minority populations. Our findings of decreasing 4 
galactosylation and sialylation in hypertensive patients are consistent with those in 5 
Chinese Han, Kazak and European populations. However, the non-significant changes 6 
of core-fucosylation and bisecting GlcNAc in hypertension patients and healthy 7 
controls are inconsistent with our previous findings in Chinese Han, Kazak and 8 
European populations. 9 
Glycans do not have a direct genetic template, thus glycan structures attached to 10 
proteins are determined by complex dynamic interactions between genetic and 11 
environmental factors.23 The HNF1A gene, known for its common variants associated 12 
with type 2 diabetes (T2DM),24 is a genetic locus significant associated with total 13 
plasma N-glycome as a regulator of fucosylation identified in the individuals of 14 
European ancestry.26 Moreover, HNF1A regulates expression of FUT8,26 and is 15 
associated with the susceptibility of T2DM in the individuals of European ancestry.27 16 
However, some variants in HNF1A and FUT8 were not statistically associated with 17 
the susceptibility of T2DM patients of Uyghur.25 The Chinese ethnic groups (e.g., 18 
Tajik, Uyghur, Kazakh, Kirgiz and Hui) are admixed populations with both eastern 19 
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and western Eurasian ancestries, thus resulting in complex genetic diversity.13 The 1 
widespread differences in genetic structure and environmental conditions among these 2 
ethnic groups may partly explain the inconsistent association between IgG Fc N-3 
glycans and hypertension among the different ethnic groups.14 4 
The marked decrease in galactosylation and increase in agalactosylation of the 5 
three subclasses (IgG 1, 2 and 4) observed in this study have been demonstrated in 6 
many other diseases and traits, such as the Parkinson’s disease and the effects of age 7 
on allergic disease.8,26 Additionally, in many autoimmune diseases, such as 8 
rheumatoid arthritis (RA), systemic lupus erythematosus, juvenile onset chronic 9 
arthritis, and Crohn’s disease, marked increase in agalactosylation has been 10 
demonstrated.27-29 It can be assumed that the increase in agalactosylation and the 11 
resulting pro-inflammatory effect may be associated with many other diseases. Lack 12 
of galactosylation is associated with a pro-inflammatory state of IgG through 13 
activation of the complement cascade.30 The previous study also demonstrated that 14 
high galactosylation promotes cooperative signaling of the FcγRIIB with dectin-1 15 
resulting in an inhibitory signaling pathway that blocks pro-inflammatory effector 16 
functions.31 A possible explanation for this decreased galactosylation is post-17 
translational modifications of the enzyme β4-galactosyltransferase-1.32 Thus the 18 
decrease in galactosylation may be the common pathogeny of multiple diseases 19 
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associated with decreased immunosuppressive potential of circulating IgG. 1 
We find that sialylation of IgG1 and IgG2 decreased in individuals with the state 2 
of hypertension. With regards to IgG4, the observed differences could have been 3 
attributed to a decrease in analytical precision resulting from the low concentrations 4 
of IgG4 in comparison to other IgG subclasses. More work is required, in particular 5 
on antigen specific IgG subclasses, to improve our understanding of the role of IgG 6 
glycosylation.  7 
Sialylation plays an important role in the inflammatory potential of IgG. 8 
Addition of sialic acid to IgG converts its function from pro- to anti-inflammatory by 9 
decreased binding to Fcγ receptors.33 IgG acquires anti-inflammatory properties upon 10 
Fc sialylation, which is reduced upon the induction of an antigen-specific immune 11 
response. This differential sialylation may provide a switch from innate anti-12 
inflammatory activity in the steady state to generating adaptive pro-inflammatory 13 
effects upon antigenic challenge.32 Therefore decreased sialylation might play 14 
pathogenic roles in hypertension, but the pathogenic mechanism of sialylation was 15 
unclear. 16 
Alterations of the immune response have been implicated in the pathogenesis of 17 
hypertension for more than 5 decades.15 Chae et al observed significantly graded 18 
relationships between blood pressure and levels of sICAM-1 as well as IL-6, which 19 
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suggested the increased blood pressure should be a stimulus for inflammation.34 1 
Marvar et al further found that hypertension has been involved in both central and 2 
peripheral mechanisms of Tlymphocyte activation and vascular inflammation 3 
produced by angiotensin II-induced hypertension.35 Additionally, several 4 
inflammatory markers including C-reactive protein (CRP) are strongly associated 5 
with the risk of hypertension.36 Therefore, the association between inflammation and 6 
hypertension suggest that IgG glycosylation might contribute to the pathogenesis of 7 
hypertension via the alternation of the inflammation, and as such could be a valuable 8 
prognostic model for hypertension. 9 
As glycan profiles are associated with genetic, metabolic and environmental 10 
influences, this adds to their predictive potential. We observed a modest improvement 11 
when adding the IgG Fc N-glycopeptide profiles to clinical risk factors. The AUC of 12 
the glycan-based model indicated that the IgG glycan profiles provide more 13 
information reinforcing current models utilizing gender, age, BMI and ethnicity.  14 
The case-control nature of this study makes it impossible to infer the causal-15 
effect relationship between IgG Fc N-glycans and hypertension. One of the 16 
shortcomings in this study is the lack of prospective follow-up for the hypertension 17 
outcome. While the study design adopted in this project shows a significant 18 
association between hypertension and IgG subclass-specific Fc N-glycopeptide 19 
20 
 
glycosylation, it is not conclusive as to whether the expressed IgG subclass Fc N-1 
glycopeptide glycosylation proceeds the symptoms of hypertension in the study 2 
cohorts. As such, no causal claims can be made as the AUCs can only be interpreted 3 
in a case-control setting where patients have already been diagnosed for and are being 4 
treated for this health event. Notwithstanding this, the current study not only presents 5 
the potential for the IgG subclass-specific glycan information to be indicative of 6 
hypertension, but additionally reinforces current diagnostic models of hypertension. 7 
Another potential limitation of this study was that some cases were on their 8 
antihypertensive medication when their blood samples were collected. Thus, it was 9 
not possible to distinguish between antihypertensive medication effects on the IgG 10 
glycome and effects associated with the pathophysiology of the disease itself. It 11 
should be noted that other risk factors related to hypertension, such as family history 12 
of hypertension and smoking, were not obtainable during this study and were not 13 
included. The absence of controlling for potential risk factors may confound the 14 
association, but at certain extend the consistent results among populations 15 
investigated with different ethnic background might help this study to profile 16 
objectively the association observed between IgG glycosylation and hypertension. 17 
Future studies in prospective cohorts should be conducted to investigate how this 18 
biomarker potential could be used for personalized approaches in prevention and 19 
21 
 
treatment of the disease as well as its role in hypertension complications. 1 
To conclude, we found that the robust associations of subclass-specific IgG Fc 2 
N- glycosylation profiles may serve as an informative biomarker indicative of the pro-3 
inflammatory and biological state shared by hypertension. Future studies should be 4 
directed at in-depth pathophysiological insights that can be derived from IgG Fc N-5 
glycan associations with hypertension. It is expected that prospective follow-up 6 
studies with additional information about inflammatory biomarkers and genetic 7 
studies might further shed light on the causality, the potential as a biomarker for 8 
complex inflammatory processes, and the true predictive capacity of IgG subclass 9 
specific Fc N-glycans in hypertension. 10 
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Figure Legends: 2 
 3 
Figure 1 Comparisons of derived subclass-specific IgG Fc N-glycomic composition 4 
between hypertension patients and healthy controls. 5 
Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the 6 
median. Lines outside the boxes represent the 2.5th and 97.5th percentiles.  7 
Figure 2 ROC curve illustrated the performance of the models in diagnosing 8 
hypertension of the four ethnic groups.  9 
When glycan traits are added into the glycan-based model, the AUCs indicated that 10 
the IgG glycan profiles provide more information reinforcing the baseline models 11 
utilizing gender, age, BMI and ethnicity. (difference between AUCs, 0.044, 95% CI: 12 
0.016 - 0.072, P= 0.002). 13 
ROC = receiver operating characteristic; AUC = area under the curve  14 
 15 
 Figure 1 
 
 Figure 2 
 
Table 1. Characteristics of the study subjects in pooling of the four ethnic groups 1 
Variables 
Hypertension 
(n=274) 
Control group 
(n=356) 
P values 
Age (years) 57.07±12.42 49.83±14.88 <0.001* 
Gender (male) 126 (50.80%) 122 (40.90 %) <0.001* 
BMI (kg/m2) 26.76±4.59 24.92±4.71 <0.001* 
SBP (mmHg) 151.20±18.44 112.67±11.83 <0.001* 
DBP (mmHg) 94.58±12.49 71.72±9.18 <0.001* 
TC (mmol/L) 4.72±1.11 4.41±1.20  0.004* 
TG (mmol/L) 2.82±0.99 2.84±1.37 0.989 
HDL (mmol/L) 1.83±0.75 1.61±0.70 <0.001* 
LDL (mmol/L) 2.72±1.62 2.29±1.10 <0.001* 
FBG (mmol/L) 5.90±1.40 5.40±1.31 <0.001* 
Dyslipidemia 206 (75.18%) 289 (81.12%) 0.069 
Data are shown as mean ± standard deviation. 2 
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: Total 3 
cholesterol; TG: Triglycerides; HDL: high-density lipoprotein cholesterol; LDL: low-density 4 
lipoprotein cholesterol; FBG: fasting blood glucose.  5 
Mann-Whitney U test: Age, BMI, SBP, DBP, TC, TG, HDL, LDL, FBG, Dyslipidemia; χ2 test: 6 
Gender. 7 
* P<0.05 was considered statistically significant. 8 
Table 2. Directly measured subclass-specific IgG Fc N-glycomic composition in the hypertension 1 
patients and the healthy controls for the pooling of the four ethnic groups. 2 
  Median (IQR)       
Glycans Hypertension Control group AOR (95% CI) P-adjusted FDR 
IgG1G0F 25.79 (21.39,30.29) 23.20 (19.69,27.92) 1.05 (1.02,1.08) 5.00E-04 7.50E-03* 
IgG2G0F 32.96 (27.35,39.22) 30.62 (25.11,35.99) 1.05 (1.02,1.07) 2.00E-04 1.20E-02* 
IgG2G1FN 4.67 (3.71,5.47) 4.83 (3.92,5.66) 0.80 (0.69,0.92) 2.50E-03 2.14E-02* 
IgG2G1FS 3.64 (3.07,4.28) 3.99 (3.22,4.52) 0.74 (0.61,0.90) 2.40E-03 2.40E-02* 
IgG2G2S 0.42 (0.25,0.62) 0.45 (0.23,0.78) 0.44 (0.25-0.79) 6.00E-03 4.00E-02* 
IgG4G0F 17.53 (12.12,24.14) 14.66 (10.81,20.97) 1.05 (1.02,1.07) 3.00E-04 6.00E-03* 
IgG4G1FS 2.36 (1.77,2.92) 2.42 (1.67,3.07) 0.73 (0.59,0.91) 5.20E-03 3.90E-02* 
IgG4G1S 0.33 (0.25,0.40) 0.35 (0.24,0.44) 0.10 (0.02,0.42) 1.70E-03 2.04E-02* 
IgG4G2FS 5.40 (3.89,7.64) 6.35 (4.45,8.55) 0.89 (0.83,0.95) 2.00E-04 1.20E-02* 
IgG4G2N 1.74 (1.09,2.29) 1.77 (1.23,2.46) 0.79 (0.66,0.94) 7.50E-03 4.50E-02* 
False discovery rate (FDR) was controlled using Benjamini–Hochberg procedure.  3 
Only the directly measured subclass-specific IgG Fc N-glycan traits which presented significant 4 
differences describing glycomic composition are shown. The other directly measured N-glycan 5 
traits are available in Supplementary Table S2. 6 
Logistic regression controlled for gender, age, BMI, dyslipidemia, FBG and ethnicity  7 
* P<0.05 was considered statistically significant. 8 
Table 3. Derived subclass-specific IgG Fc N-glycomic composition in the hypertension patients and 1 
healthy controls for the pooling of the four ethnic groups. 2 
  Median (IQR)       
Glycans Hypertension Control group AOR (95% CI) P-adjusted FDR 
A1 37.04 (31.81,43.13) 33.76 (27.55,39.74) 1.04 (1.02,1.06) 1.30E-03 6.07E-03* 
M1 37.50 (35.63,38.86) 37.93 (36.17,39.37) 0.93 (0.87,0.99) 1.50E-02 3.50E-02* 
D1 12.38 (10.37,15.20) 14.23 (11.35,17.79) 0.95 (0.90,0.99) 2.14E-02 4.28E-02* 
G1 50.28 (46.67,53.90) 52.74 (48.48,56.46) 0.96 (0.93,0.99) 6.00E-03 1.87E-02* 
S1 11.58 (9.23,13.86) 12.20 (9.69,14.92) 0.93 (0.89,0.98) 1.04E-02 2.91E-02* 
A2 42.59 (36.51,49.42) 39.25 (32.65,45.60) 1.04 (1.02,1.06) 5.00E-04 4.67E-03* 
M2 33.01 (31.01,35.18) 33.87 (31.95,35.35) 0.91 (0.86,0.96) 1.00E-03 5.60E-03* 
D2 11.81 (9.68,15.11) 13.82 (10.72,17.12) 0.93 (0.89,0.97) 2.30E-03 9.20E-03* 
G2 45.39 (41.10,50.02) 47.90 (43.56,52.31) 0.95 (0.92,0.98) 4.00E-04 5.60E-03* 
S2 10.29 (8.05,12.83) 11.54 (8.74,14.43) 0.93 (0.89,0.98) 5.10E-03 1.79E-02* 
A4 24.30 (17.77,31.96) 20.26 (15.26,27.63) 1.03 (1.01,1.05) 8.00E-04 5.60E-03* 
M4 26.89 (23.81,29.82) 27.76 (24.02,30.96) 0.96 (0.93,0.99) 1.88E-02 4.05E-02* 
D4 22.10 (18.15,25.35) 23.82 (20.28,27.80) 0.96 (0.93,0.99) 1.25E-02 3.18E-02* 
G4 48.17 (45.17,52.74) 51.39 (47.15,56.26) 0.95 (0.92,0.97) 1.00E-04 2.80E-03* 
False discovery rate (FDR) was controlled using Benjamini–Hochberg procedure. 3 
A, agalactosylation; M, monogalactosylation; D, digalactosylation; G, galactosylation; S, sialylation; 4 
B, bisecting GlcNAc; F, fucosylation. Number represents specific IgG subclass. 5 
Only the derived subclass-specific IgG Fc N-glycan traits which presented significant differences 6 
describing glycomic composition are shown. The other derived N-glycan traits are available in 7 
Supplementary Table S3 8 
Logistic regression controlled for gender, age, BMI, dyslipidemia, FBG, and ethnicity 9 
* P<0.05 was considered statistically significant. 10 
Table 4. The glycan-based model included the significantly differed subclass-specific IgG Fc 1 
glycopeptide N-glycans together with gender, age, BMI and ethnicity 2 
Variables β S.E. Wald χ2 AOR P values 95% CI 
Gender -0.37  0.18  4.12  0.69  4.24E-02 (0.48,0.99) 
Age 0.02  0.01  11.85  1.03  5.77E-04 (1.01,1.04) 
BMI 0.09  0.02  22.59  1.10  2.00E-06 (1.06,1.14) 
Ethnicity -0.30  0.09  10.67  0.74  1.09E-03 (0.62,0.89) 
IgG1G0F 0.01  0.02  0.44  1.01  5.07E-01 (0.98,1.05) 
IgG2G0F 0.00  0.02  0.02  1.00  8.87E-01 (0.97,1.04) 
IgG4G0F 0.02  0.02  2.29  1.02  1.30E-01 (0.99,1.06) 
IgG4G2FS -0.12  0.04  9.56  0.88  1.99E-03 (0.82,0.96) 
IgG4G2N -0.20  0.11  3.54  0.82  6.00E-02 (0.67,1.01) 
AOR = adjusted odds ratio; 95%CI = 95% confidence interval. 3 
Table S1． Characteristics of the study subjects in the four ethnic groups: Uygur, Kazak, Kirgiz and Tajik
Hypertension 
(n=90)
Control group 
(n=80) P values
Hypertension 
(n=52)
Control group 
(n=98) P values
Hypertension 
(n=90)
Age (years) 62.88±11.62 59.19±13.83 0.061 49.33±10.48 41.68±10.97 <0.001* 54.85±12.92
Gender (male) 25(27.8%) 40(50.0%) 0.338 25(48.1%) 20(20.4%) <0.001* 38(42.2%)
BMI (kg/m2) 25.41±4.95 24.71±4.76 0.349 25.83±4.08 22.68±4.38 <0.001* 28.97±3.90
SBP (mmHg) 151.09±18.44 115.75±8.83 <0.001* 149.46±15.08 105.92±12.67 <0.001* 156.37±22.93
DBP (mmHg) 96.39±12.75 73.44±6.14 <0.001* 95.58±9.18 68.27±9.97 <0.001* 92.37±15.99
TC (mmol/L) 4.88±1.29 4.77±0.95 0.54 4.42±0.76 3.35±0.96  0.004* 4.55±1.08
TG (mmol/L) 1.84±0.46 1.89±0.40 0.518 1.88±0.71 1.15±0.53 0.989 1.70±0.44
HDL (mmol/L) 3.61±2.21 3.09±0.77 0.049 2.75±0.78 2.19±0.93 <0.001* 2.72±0.81
LDL (mmol/L) 2.90±0.73 3.32±1.48 0.020* 1.85±0.50 1.59±0.79 <0.001* 2.72±0.83
FBG (mmol/L) 6.23±1.41 6.11±1.02 0.542 5.37±1.10 4.56±1.00 <0.001* 5.83±1.48
Data are shown as mean ± standard deviation.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: Total cholesterol; TG                
Mann-Whitney U test: Age, BMI, SBP, DBP, TC, TG, HDL, LDL, FBG; χ2 test: Gender.
* P <0.05 was considered statistically significant.
Variables
UIG KZK
Control group 
(n=78) P values
Hypertension 
(n=65)
Control group 
(n=77) P values
40.96±12.12 <0.001* 54.85±12.92 40.96±12.12 <0.001*
27（34.6%） 0.091 38(56.7%) 34(33.7%) 0.091
27.53±3.70 0.026 28.97±3.90 27.53±3.70 0.026
117.79±9.43 <0.001* 156.37±22.93 117.79±9.43 <0.001*
72.84±10.08 <0.001* 92.37±15.99 72.84±10.08 <0.001*
4.79±1.23 0.223 4.56±1.12 4.74±1.28 0.279
1.68±0.41 0.805 2.74±0.84 2.78±1.25 0.834
2.93±1.04 0.180 1.71±0.52 1.72±0.45 0.979
2.75±1.20 0.864 2.72±0.81 2.93±1.04 0.180
5.44±1.50 0.128 5.80±1.50 5.40±1.54 0.124
               G: Triglycerides;  HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol;     
TJKKGZ
                          FBG: fasting blood glucose. 
age 假设方差相
等
.601 .440 -6.598 140 .000 40.96 12.119
BMI 假设方差相
等
.000 .999 -2.253 140 .026 27.5303 3.70212
SBP 假设方差相
等
39.486 .000 -13.482 140 .000 117.79 9.433
DBP 假设方差相
等
4.220 .042 -8.838 140 .000 72.84 10.081
TC 假设方差相
等
4.832 .030 -1.086 140 .279 4.7391 1.27868
HDL 假设方差相
等
1.136 .288 .026 140 .979 1.7168 .44732
LDL 假设方差相
等
5.689 .018 1.347 140 .180 2.9322 1.03752
TG 假设方差相
等
1.916 .168 .210 140 .834 2.7762 1.24591
GLU 假设方差相
等
.191 .663 -1.549 140 .124 5.4038 1.53688
4.5568
1.12102
0 356 2.61 1.114 .059
1 274 2.30 1.118 .068
0 356 .81 .391 .021
1 274 .75 .433 .026 27.5303
12.119 3.70212
nation
HC
40.96 12.12 40.96±12.12
27.53 3.70 27.53±3.7
117.79 9.43 117.79±9.43
72.84 10.08 72.84±10.08
4.74 1.28 4.74±1.28
1.72 0.45 1.72±0.45
2.93 1.04 2.93±1.04
2.78 1.25 2.78±1.25
5.40 1.54 5.4±1.54
117.79 72.84 4.7391 1.7168 2.9322 2.7762 5.4038
9.433 10.081 1.27868 .44732 1.03752 1.24591 1.53688
Hypertensio
n (n=90)
Controls 
(n=80)
Hypertensi
on (n=52)
Controls  
(n=98)
Hypertensio
n (n=90)
Controls  
(n=78)
Hypertensio
n (n=65)
Age (years) 62.88±11.62 59.19±13.8349.33±10.4841.68±10.97 54.85±12.92 40.96±12.12 54.85±12.92
Gender (male) 25(27.8%) 40(50.0%) 25(48.1%) 20(20.4%) 38(42.2%) 27（34.6%） 38(56.7%)
Variables
UIG KZK KGZ T
Controls  
(n=77)
40.96±12.12
34(33.7%)
JK
Logistic regression Logistic regression
Z P values P-adjusted Z P values P-adjusted
IgG1G0 -0.71 4.80E-01 1.91E-01 -0.19 8.50E-01 1.45E-01
IgG1G0F -2.28 2.24E-02 9.77E-02 -4.77 1.84E-06 2.90E-03
IgG1G0FN -1.53 1.25E-01 1.53E-01 -0.99 3.22E-01 6.54E-01
IgG1G0N -0.64 5.23E-01 2.28E-01 -3.02 2.49E-03 1.92E-02
IgG1G1 -1.88 6.01E-02 6.69E-02 -0.35 7.25E-01 3.01E-01
IgG1G1F -0.42 6.73E-01 6.53E-01 -2.91 3.56E-03 1.94E-02
IgG1G1FN -0.21 8.31E-01 9.07E-01 -3.94 8.11E-05 1.09E-02
IgG1G1FNS -0.18 8.57E-01 4.08E-01 -5.34 9.14E-08 2.00E-04
IgG1G1FS -1.40 1.60E-01 1.42E-01 -1.90 5.70E-02 7.16E-01
IgG1G1N -0.22 8.29E-01 1.58E-01 -1.66 9.64E-02 7.16E-02
IgG1G1NS -1.23 2.20E-01 4.74E-01 -2.00 4.53E-02 3.16E-02
IgG1G1S -1.55 1.21E-01 5.81E-01 -1.71 8.73E-02 7.99E-02
IgG1G2 -1.44 1.51E-01 1.33E-01 -2.54 1.10E-02 5.79E-02
IgG1G2F -0.87 3.83E-01 6.96E-01 -4.42 9.74E-06 3.00E-03
IgG1G2FN -1.56 1.19E-01 5.16E-01 -2.19 2.87E-02 1.96E-01
IgG1G2FNS -0.36 7.21E-01 5.38E-01 -2.74 6.06E-03 1.60E-03
IgG1G2FS -0.96 3.39E-01 5.54E-01 -2.78 5.43E-03 1.21E-01
IgG1G2N 0.00 1.00E+00 2.16E-01 -1.26 2.09E-01 4.23E-01
IgG1G2NS 0.00 1.00E+00 7.02E-01 -1.54 1.23E-01 1.46E-02
IgG1G2S -1.99 4.61E-02 1.25E-01 -1.50 1.33E-01 3.94E-01
IgG2G0 -1.23 2.20E-01 1.11E-01 -2.01 4.40E-02 6.91E-02
IgG2G0F -0.09 9.28E-01 8.80E-01 -5.89 3.91E-09 <.0001
IgG2G0FN -0.33 7.45E-01 6.34E-01 -1.82 6.93E-02 1.85E-01
IgG2G0N -0.70 4.86E-01 1.51E-01 -3.96 7.59E-05 3.70E-03
IgG2G1 -1.54 1.25E-01 8.18E-01 -0.91 3.62E-01 4.51E-01
IgG2G1F -0.54 5.88E-01 4.15E-01 -3.43 6.00E-04 2.30E-03
IgG2G1FN -0.35 7.25E-01 6.65E-01 -6.52 7.23E-11 <.0001
IgG2G1FNS -1.11 2.66E-01 1.52E-01 -4.95 7.49E-07 <.0001
IgG2G1FS -0.27 7.84E-01 7.85E-01 -3.72 2.02E-04 1.00E-03
IgG2G1N -0.29 7.70E-01 9.62E-01 -0.19 8.50E-01 2.59E-01
IgG2G1NS 0.00 1.00E+00 7.67E-01 -0.25 7.99E-01 6.72E-01
IgG2G1S -1.35 1.76E-01 1.59E-01 -2.51 1.20E-02 3.48E-02
IgG2G2 -0.49 6.28E-01 3.74E-01 -4.48 7.53E-06 1.23E-02
IgG2G2F -0.01 9.92E-01 7.76E-01 -4.70 2.56E-06 2.00E-04
IgG2G2FN -0.10 9.21E-01 7.62E-01 -4.11 3.94E-05 7.00E-04
IgG2G2FNS -0.14 8.88E-01 9.34E-01 -0.59 5.54E-01 2.74E-01
IgG2G2FS -0.20 8.44E-01 8.18E-01 -3.05 2.27E-03 1.49E-02
IgG2G2N -1.34 1.79E-01 7.50E-01 -4.94 7.96E-07 5.00E-04
IgG2G2NS 0.00 1.00E+00 8.84E-01 -1.33 1.82E-01 1.35E-02
IgG2G2S -0.03 9.73E-01 1.22E-01 -1.63 1.03E-01 7.65E-01
IgG4G0 -0.67 5.05E-01 1.72E-01 -2.98 2.87E-03 5.09E-01
IgG4G0F -0.17 8.65E-01 8.49E-01 -7.34 2.18E-13 <0.0001
IgG4G0FN -0.29 7.72E-01 6.19E-01 -5.75 8.73E-09 <.0001
IgG4G0N -0.81 4.15E-01 3.01E-01 -2.97 3.02E-03 1.09E-01
Table S2.  Directly measured subclass-specific IgG Fc N -glycomic  composition in hypertension p                    
Glycans
UIG KZK
Mann-Whitney test Mann-Whitney test
IgG4G1 -1.43 1.51E-01 3.02E-01 -4.60 4.13E-06 <.0001
IgG4G1F -1.11 2.65E-01 3.03E-01 -0.83 4.05E-01 3.42E-01
IgG4G1FN -0.52 6.05E-01 5.13E-01 -1.55 1.22E-01 2.54E-01
IgG4G1FNS -0.17 8.63E-01 7.64E-01 -0.57 5.67E-01 3.59E-01
IgG4G1FS -0.38 7.02E-01 1.42E-01 -0.40 6.87E-01 9.60E-01
IgG4G1N -1.06 2.89E-01 3.19E-01 -4.94 7.80E-07 <.0001
IgG4G1NS -0.95 3.40E-01 4.43E-01 -1.57 1.16E-01 2.90E-01
IgG4G1S -0.93 3.54E-01 5.35E-02 -0.78 4.34E-01 8.20E-03
IgG4G2 -0.24 8.09E-01 6.68E-01 -4.00 6.33E-05 1.80E-03
IgG4G2F -1.85 6.48E-02 2.00E-01 -2.72 6.43E-03 2.88E-02
IgG4G2FN -1.94 5.28E-02 2.67E-01 -1.61 1.07E-01 4.29E-01
IgG4G2FNS -2.50 1.23E-02 3.20E-01 -3.04 2.33E-03 1.39E-01
IgG4G2FS -2.01 4.46E-02 5.72E-02 -4.02 5.82E-05 1.00E-03
IgG4G2N -0.87 3.83E-01 4.52E-01 -7.17 7.42E-13 <0.0001
IgG4G2NS -1.16 2.48E-01 6.47E-01 -2.32 2.02E-02 1.13E-01
IgG4G2S -0.20 8.44E-01 2.58E-01 -1.15 2.49E-01 5.04E-01
False discovery rate (FDR) was controlled using Benjamini–Hochberg procedure. 
Bold in P- adjusted represent P <0.05.
Logistic regression controlled for gender, age, BMI, dyslipidemia, FBG and ethnicity
Logistic regression Logistic regression
Z P values P-adjusted Z P values P-adjusted
-1.08 2.79E-01 3.81E-01 -1.91 5.61E-02 4.73E-01
-0.88 3.80E-01 8.61E-01 -3.19 1.40E-03 7.78E-01
-0.74 4.57E-01 6.09E-01 -3.47 5.28E-04 8.90E-01
-1.16 2.45E-01 3.42E-01 -2.15 3.19E-02 3.02E-01
-0.07 9.43E-01 5.32E-01 -0.53 5.99E-01 3.95E-01
-0.13 8.96E-01 7.12E-01 -0.71 4.75E-01 5.89E-01
-0.31 7.60E-01 6.98E-01 -0.13 8.98E-01 2.99E-01
-0.37 7.08E-01 6.76E-01 -0.63 5.30E-01 7.11E-01
-0.45 6.51E-01 5.21E-01 -0.85 3.97E-01 7.67E-01
-0.39 6.96E-01 4.37E-01 -0.11 9.13E-01 2.51E-01
-1.36 1.72E-01 2.92E-01 0.00 1.00E+00 1.37E-01
-0.43 6.67E-01 5.37E-01 -2.40 1.64E-02 1.96E-01
-0.46 6.44E-01 7.53E-01 -1.97 4.89E-02 9.02E-01
-0.86 3.92E-01 8.06E-01 -3.38 7.34E-04 6.31E-01
-0.88 3.77E-01 9.71E-01 -2.12 3.43E-02 5.61E-01
-0.72 4.73E-01 7.59E-01 -1.94 5.29E-02 9.52E-01
-0.63 5.26E-01 3.27E-01 -3.65 2.58E-04 9.34E-01
-0.34 7.31E-01 8.12E-01 -0.92 3.58E-01 6.63E-01
-0.22 8.29E-01 8.33E-01 0.00 1.00E+00 5.03E-01
-0.48 6.28E-01 4.19E-01 -2.12 3.40E-02 9.20E-01
-0.08 9.33E-01 2.97E-01 -0.04 9.66E-01 4.58E-01
-1.04 2.99E-01 5.14E-01 -3.21 1.35E-03 8.59E-01
-1.40 1.63E-01 1.77E-01 -2.89 3.80E-03 8.09E-01
-0.10 9.20E-01 5.94E-01 -0.07 9.42E-01 5.43E-01
-0.26 7.98E-01 7.70E-01 -0.46 6.44E-01 2.25E-01
-0.51 6.11E-01 3.48E-01 -1.46 1.45E-01 4.24E-01
-0.67 5.02E-01 5.10E-01 -1.00 3.17E-01 9.57E-01
-0.66 5.08E-01 7.10E-01 -0.19 8.46E-01 9.17E-01
-1.60 1.11E-01 1.70E-02 -1.88 5.97E-02 9.82E-01
-0.67 5.02E-01 7.39E-01 -0.70 4.86E-01 2.71E-01
-0.99 3.24E-01 5.81E-01 0.00 1.00E+00 5.34E-01
-1.68 9.24E-02 7.86E-02 -0.68 4.97E-01 6.35E-01
-0.09 9.25E-01 7.49E-01 -1.48 1.38E-01 2.95E-01
-1.37 1.71E-01 2.78E-01 -2.94 3.24E-03 3.87E-01
-1.26 2.08E-01 2.28E-01 -1.80 7.21E-02 8.81E-01
-1.43 1.52E-01 2.71E-01 -0.81 4.16E-01 8.57E-01
-1.52 1.28E-01 9.91E-02 -3.26 1.12E-03 7.99E-01
-0.22 8.25E-01 7.08E-01 -0.66 5.08E-01 3.16E-01
-0.82 4.10E-01 5.18E-01 0.00 1.00E+00 1.77E-01
-1.39 1.64E-01 2.20E-01 -3.00 2.74E-03 6.84E-01
-1.21 2.26E-01 3.60E-01 -1.57 1.17E-01 6.56E-01
-0.57 5.72E-01 9.69E-01 -2.45 1.44E-02 7.34E-01
-0.04 9.65E-01 7.18E-01 -3.09 2.01E-03 8.91E-01
-0.99 3.24E-01 3.01E-01 -1.09 2.76E-01 2.93E-01
             atients and healthy controls for each of the four ethnic groups  and the pooling of the four ethn  
TJK
Mann-Whitney test Mann-Whitney test
KGZ
-0.32 7.53E-01 9.37E-01 -2.10 3.57E-02 6.72E-01
-0.45 6.51E-01 9.73E-01 -0.02 9.82E-01 4.80E-01
-0.24 8.10E-01 9.98E-01 -1.17 2.43E-01 8.69E-01
-1.30 1.94E-01 3.99E-01 -0.48 6.34E-01 8.04E-01
-0.83 4.06E-01 2.02E-01 -1.14 2.55E-01 2.33E-01
-0.43 6.64E-01 9.44E-01 -2.53 1.14E-02 5.84E-01
-1.13 2.58E-01 5.43E-01 -1.54 1.22E-01 6.62E-02
-0.78 4.35E-01 6.13E-01 -0.11 9.10E-01 9.78E-01
-0.19 8.49E-01 4.58E-01 -0.93 3.50E-01 4.83E-01
-0.07 9.40E-01 8.82E-01 -2.65 8.08E-03 6.42E-01
-0.84 3.99E-01 7.07E-01 -1.32 1.87E-01 9.21E-01
-1.16 2.47E-01 2.81E-01 -2.48 1.30E-02 9.83E-01
-0.45 6.51E-01 3.93E-01 -2.67 7.51E-03 5.42E-01
-0.73 4.63E-01 8.06E-01 -1.26 2.08E-01 8.39E-01
-1.90 5.69E-02 3.88E-01 0.00 1.00E+00 7.36E-01
-0.97 3.32E-01 5.75E-01 -1.79 7.42E-02 6.22E-01
Logistic regression
Z P values P-adjusted
-0.19 8.50E-01 4.02E-01 4.72E-01
-4.77 1.84E-06 5.00E-04 7.50E-03
-0.99 3.22E-01 2.72E-01 3.63E-01
-3.02 2.49E-03 8.70E-01 8.70E-01
-0.35 7.25E-01 7.66E-01 8.21E-01
-2.91 3.56E-03 3.05E-01 3.90E-01
-3.94 8.11E-05 4.65E-02 1.21E-01
-5.34 9.14E-08 8.50E-01 8.65E-01
-1.90 5.70E-02 6.46E-02 1.55E-01
-1.66 9.64E-02 4.53E-01 5.13E-01
-2.00 4.53E-02 7.09E-02 1.58E-01
-1.71 8.73E-02 4.70E-02 1.18E-01
-2.54 1.10E-02 4.01E-02 1.20E-01
-4.42 9.74E-06 3.73E-02 1.18E-01
-2.19 2.87E-02 6.17E-02 1.54E-01
-2.74 6.06E-03 8.39E-01 8.83E-01
-2.78 5.43E-03 6.94E-02 1.60E-01
-1.26 2.09E-01 8.92E-02 1.85E-01
-1.54 1.23E-01 4.26E-01 4.91E-01
-1.50 1.33E-01 3.41E-02 1.14E-01
-2.01 4.40E-02 3.33E-01 4.00E-01
-5.89 3.91E-09 2.00E-04 1.20E-02
-1.82 6.93E-02 2.73E-01 3.55E-01
-3.96 7.59E-05 8.44E-01 8.73E-01
-0.91 3.62E-01 1.42E-01 2.44E-01
-3.43 6.00E-04 3.18E-01 3.97E-01
-6.52 7.23E-11 2.50E-03 2.14E-02
-4.95 7.49E-07 9.36E-02 1.81E-01
-3.72 2.02E-04 2.40E-03 2.40E-02
-0.19 8.50E-01 2.31E-01 3.15E-01
-0.25 7.99E-01 4.61E-01 5.13E-01
-2.51 1.20E-02 1.24E-02 6.76E-02
-4.48 7.53E-06 2.26E-02 1.04E-01
-4.70 2.56E-06 2.98E-02 1.12E-01
-4.11 3.94E-05 2.75E-02 1.18E-01
-0.59 5.54E-01 1.70E-01 2.69E-01
-3.05 2.27E-03 2.15E-02 9.92E-02
-4.94 7.96E-07 1.41E-01 2.49E-01
-1.33 1.82E-01 4.30E-02 1.23E-01
-1.63 1.03E-01 6.00E-03 4.00E-02
-2.98 2.87E-03 1.86E-01 2.87E-01
-7.34 2.18E-13 3.00E-04 6.00E-03
-5.75 8.73E-09 1.59E-01 2.57E-01
-2.97 3.02E-03 2.03E-01 2.98E-01
Mann-Whitney test
                               nic groups.
Pooling of 4 ethnic groups
FDR
-4.60 4.13E-06 9.41E-02 1.76E-01
-0.83 4.05E-01 6.98E-01 7.61E-01
-1.55 1.22E-01 8.77E-02 1.88E-01
-0.57 5.67E-01 2.26E-01 3.16E-01
-0.40 6.87E-01 5.20E-03 3.47E-02
-4.94 7.80E-07 2.15E-01 3.07E-01
-1.57 1.16E-01 1.43E-01 2.39E-01
-0.78 4.34E-01 1.70E-03 2.04E-02
-4.00 6.33E-05 3.22E-01 3.94E-01
-2.72 6.43E-03 2.80E-02 1.05E-01
-1.61 1.07E-01 1.10E-01 1.99E-01
-3.04 2.33E-03 3.01E-02 1.00E-01
-4.02 5.82E-05 2.00E-04 1.20E-02
-7.17 7.42E-13 7.50E-03 4.50E-02
-2.32 2.02E-02 1.98E-01 2.96E-01
-1.15 2.49E-01 9.29E-02 1.86E-01
Logistic regression Logistic regression
Z P values P-adjusted Z P values P-adjusted
A1 -1.83 6.74E-02 1.53E-01 -4.41 1.03E-05 4.20E-03
M1 -0.73 4.64E-01 5.90E-01 -3.76 1.73E-04 6.41E-02
D1 -1.25 2.10E-01 4.97E-01 -4.32 1.53E-05 3.50E-03
G1 -1.25 2.11E-01 4.62E-01 -4.33 1.48E-05 2.50E-03
S1 -1.82 6.83E-02 1.54E-01 -2.64 8.34E-03 1.81E-01
B1 -0.46 6.49E-01 6.89E-01 -0.56 5.75E-01 7.74E-01
F1 -2.28 2.25E-02 2.88E-02 -1.16 2.44E-01 9.98E-01
A2 -0.01 9.94E-01 8.93E-01 -5.45 4.94E-08 <.0001
M2 -0.50 6.17E-01 4.74E-01 -5.32 1.02E-07 <.0001
D2 -0.46 6.49E-01 8.51E-01 -5.17 2.30E-07 <.0001
G2 -0.18 8.55E-01 8.09E-01 -5.47 4.42E-08 <.0001
S2 -0.34 7.37E-01 7.74E-01 -3.23 1.22E-03 5.80E-03
B2 -0.14 8.90E-01 8.57E-01 -2.03 4.20E-02 1.91E-02
F2 -1.28 2.01E-01 5.14E-01 -0.46 6.47E-01 4.22E-01
A4 -0.28 7.82E-01 7.50E-01 -7.23 4.95E-13 <0.0001
M4 -0.26 7.91E-01 8.61E-01 -4.82 1.45E-06 2.00E-04
D4 -0.05 9.62E-01 9.67E-01 -6.31 2.71E-10 <.0001
G4 -0.17 8.65E-01 8.59E-01 -8.00 1.24E-15 <0.0001
S4 -0.66 5.12E-01 8.18E-01 -1.70 8.95E-02 2.04E-01
B4 -0.05 9.64E-01 8.58E-01 -0.09 9.31E-01 5.68E-01
F4 -0.98 3.29E-01 2.43E-01 -3.72 1.96E-04 2.90E-03
False discovery rate (FDR) was controlled using Benjamini–Hochberg procedure. 
Bold in P- adjusted represent P <0.05.
Logistic regression controlled for gender, age, BMI, dyslipidemia, FBG and ethnicity
A - agalactosylation, M - monogalactosylation, D- digalactosylation, G - galactosylation (total), S - s             
Table S3.  Derived subclass-specific IgG Fc N -glycomic composition in hypertension patients and h                  
Glycans
UIG KZK
Mann-Whitney test Mann-Whitney test
Logistic regression Logistic regression
Z P values P-adjusted Z P values P-adjusted Z
-1.02 3.09E-01 6.21E-01 -3.64 2.70E-04 9.44E-01 -4.41
-0.38 7.03E-01 7.79E-01 -0.30 7.67E-01 4.22E-01 -3.76
-0.88 3.77E-01 7.99E-01 -3.34 8.34E-04 7.48E-01 -4.32
-0.72 4.71E-01 9.89E-01 -3.22 1.27E-03 8.97E-01 -4.33
-0.96 3.38E-01 2.42E-01 -3.72 1.96E-04 9.33E-01 -2.64
-0.55 5.83E-01 5.50E-01 -1.86 6.24E-02 4.24E-01 -0.56
0.00 1.00E+00 5.64E-01 -0.27 7.91E-01 4.05E-01 -1.16
-1.12 2.62E-01 3.25E-01 -3.59 3.34E-04 8.90E-01 -5.45
-0.27 7.91E-01 4.06E-01 -1.01 3.14E-01 7.36E-01 -5.32
-1.30 1.92E-01 3.59E-01 -3.44 5.80E-04 8.45E-01 -5.17
-1.35 1.75E-01 3.16E-01 -2.84 4.48E-03 9.67E-01 -5.47
-1.76 7.88E-02 4.28E-02 -3.00 2.66E-03 9.02E-01 -3.23
0.00 1.00E+00 6.24E-01 -1.23 2.18E-01 7.71E-01 -2.03
-0.76 4.44E-01 1.85E-01 -0.34 7.33E-01 1.49E-01 -0.46
-0.45 6.51E-01 9.73E-01 -2.61 9.09E-03 8.10E-01 -7.23
-0.02 9.80E-01 9.44E-01 -1.62 1.06E-01 6.99E-01 -4.82
-0.64 5.24E-01 4.30E-01 -2.25 2.42E-02 5.48E-01 -6.31
-0.20 8.42E-01 5.02E-01 -0.90 3.70E-01 8.07E-01 -8.00
-0.32 7.53E-01 8.97E-01 -3.13 1.74E-03 8.07E-01 -1.70
-0.68 4.98E-01 7.22E-01 -2.69 7.14E-03 7.92E-01 -0.09
-0.02 9.88E-01 7.90E-01 -0.44 6.58E-01 5.70E-01 -3.72
              sialylation, B - bisecting GlcNAc, F - fucosylation. Number represents specific IgG subclass.
Mann-Wh  
    
             healthy controls for each of the four ethnic groups  and the pooling of the four ethnic groups.
TJK
Mann-Whitney test Mann-Whitney test
KGZ
Logistic regression
P values P-adjusted
1.03E-05 1.30E-03 6.07E-03
1.73E-04 1.50E-02 3.50E-02
1.53E-05 2.14E-02 4.28E-02
1.48E-05 6.00E-03 1.87E-02
8.34E-03 1.04E-02 2.91E-02
5.75E-01 4.74E-01 6.98E-01
2.44E-01 3.44E-01 5.35E-01
4.94E-08 5.00E-04 4.67E-03
1.02E-07 1.00E-03 5.60E-03
2.30E-07 2.30E-03 9.20E-03
4.42E-08 4.00E-04 5.60E-03
1.22E-03 5.10E-03 1.79E-02
4.20E-02 1.25E-01 2.32E-01
6.47E-01 2.29E-01 3.76E-01
4.95E-13 8.00E-04 5.60E-03
1.45E-06 1.88E-02 4.05E-02
2.71E-10 1.25E-02 3.18E-02
1.24E-15 1.00E-04 2.80E-03
8.95E-02 8.42E-01 1.12E+00
9.31E-01 2.14E-01 3.74E-01
1.96E-04 6.83E-01 9.56E-01
hitney test
Pooling of 4 ethnic groups
                              
FDR
